J. Levy
New England Journal of Medicine · 2005–2020
A researcher in the Science corpus: 6 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from J. Levy's perspective
Ordered by how strongly the researchers J. Levy trusts endorse each paper. Same corpus, a different order for every researcher.
- [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. (Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi)
- Covid-19 in Critically Ill Patients in the Seattle Region — Case Series (New England Journal of Medicine)
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia (Journal of Thrombosis and Haemostasis)
- Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy (Journal of Thrombosis and Haemostasis)
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study (The Lancet)
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. (Journal of the American Medical Association (JAMA))
- Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. (New England Journal of Medicine)
- Clinical Characteristics of Coronavirus Disease 2019 in China (Journal of Emergency Medicine)
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome (The Lancet Respiratory Medicine)
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia (New England Journal of Medicine)
Their papers
- Thromboinflammation and the hypercoagulability of COVID‐19 (2020) — 619 citations
- COVID-19 and its implications for thrombosis and anticoagulation (2020) — 2,157 citations
- Coagulation abnormalities and thrombosis in patients with COVID-19 (2020) — 1,332 citations
- Idarucizumab for Dabigatran Reversal — Full Cohort Analysis (2017) — 692 citations
- Idarucizumab for Dabigatran Reversal. (2015) — 1,551 citations
- Symposium on the definition and management of anaphylaxis: summary report. (2005) — 636 citations